SCHEMBL4684274

SCHEMBL4684274

CC1CNCC(C)N1C(=O)OCc1c(F)cc(OCCCc2ccccc2)cc1F

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2C P28335 2/20 0.60
MAOB P27338 1/20 0.38
LMNA P02545 1/20 0.38
FFAR1 O14842 2/20 0.37
ALDH1A1 P00352 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
ADORA3 P0DMS8 1/20 0.37
HTR2A P28223 1/20 0.37
HTR7 P34969 1/20 0.37
OPRM1 P35372 1/20 0.37
SIGMAR1 Q99720 1/20 0.37
PDK1 Q15118 1/20 0.36
PDK2 Q15119 1/20 0.36
PDK3 Q15120 1/20 0.36
PDK4 Q16654 1/20 0.36
NAAA Q02083 2/20 0.36
REN P00797 1/20 0.36
KCNH2 Q12809 1/20 0.36
S1PR1 P21453 3/20 0.36
CACNA1G O43497 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4684272 1.00 HTR2C (0.60) HTR2CMAOBLMNAFFAR1ALDH1A1
Fumaric Acid SCHEMBL4680932 0.95 HTR2C (0.55) HTR2CMAOBLMNAFFAR1ALDH1A1
Fumaric Acid SCHEMBL4680929 0.95 HTR2C (0.55) HTR2CMAOBLMNAFFAR1ALDH1A1
SCHEMBL4680806 0.87 HTR2C (0.58) HTR2CMAOBFFAR1S1PR1MTNR1A
SCHEMBL4680803 0.87 HTR2C (0.58) HTR2CMAOBFFAR1S1PR1MTNR1A
SCHEMBL4680858 0.84 HTR2C (0.66) HTR2CLMNAALDH1A1SMN1; SMN2NAAA
SCHEMBL4681265 0.83 HTR2C (0.62) HTR2CMAOB
SCHEMBL4681268 0.83 HTR2C (0.62) HTR2CMAOB
SCHEMBL4682222 0.82 HTR2C (0.59) HTR2CMAOBFFAR1MTNR1AMTNR1B
SCHEMBL4682225 0.82 HTR2C (0.59) HTR2CMAOBFFAR1MTNR1AMTNR1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1343775-B1 PIPERAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-06-04 EP disclosed
US-7022707-B2 Piperazine derivatives HOFFMAN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20040235859-A1 Novel piperazine derivatives ADAMS DAVID REGINALD (GB) 2004-11-25 US disclosed
EP-1343775-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-09-17 EP disclosed
US-20020143020-A1 Novel piperazine derivatives VERNALIS RESEARCH LIMITED (GB) 2002-10-03 US disclosed
WO-2002048124-A2 PIPERAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020143020-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 HTR2C 289/4885MAOB 2221/4885LMNA 4209/4885
US-20040235859-A1 Novel piperazine derivatives CYP4B1, UGT1A1, CYP1B1 HTR2C 289/4885MAOB 2221/4885LMNA 4209/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.